Neuromod Devices
A pioneer in the development of bimodal neuromodulation treatments.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | €10.0m Valuation: €75.0m | Series B | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | (38 %) | (54 %) |
| EBITDA | 0000 | 0000 | 0000 |
| % EBITDA margin | 1038 % | 1462 % | 4049 % |
| Profit | 0000 | 0000 | 0000 |
| % profit margin | 100 % | 100 % | 100 % |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.
We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control of their own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.
Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'.